Molecular cytogenetic characterization in four pediatric pheochromocytomas and paragangliomas
Language English Country Switzerland Media print-electronic
Document type Case Reports, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Chromosome Aberrations MeSH
- Cytogenetics MeSH
- Pheochromocytoma genetics MeSH
- Humans MeSH
- Adolescent MeSH
- Adrenal Gland Neoplasms genetics MeSH
- Paraganglioma genetics MeSH
- Comparative Genomic Hybridization methods MeSH
- von Hippel-Lindau Disease genetics MeSH
- Germ-Line Mutation MeSH
- Check Tag
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Research Support, Non-U.S. Gov't MeSH
Pheochromocytomas (PCCs) are rare tumors among children and adolescents and therefore are not genetically well characterized. The most frequently observed chromosomal changes in PCC are losses of 1p, 3q and/or 3p, 6q, 17p, 11q, 22q, and gains of 9q and 17q. Aberrations involving chromosome 11 are more common in malignant tumors. Unfortunately information about gene aberrations in childhood PCC's is limited. We used comparative genomic hybridization (CGH) and array comparative genomic hybridization (aCGH) to screen for copy number changes in four children suffering from pheochromocytoma or paraganglioma. Patients were diagnosed at the age 13 or 14 years. Bilateral pheochromocytoma was associated with von Hippel-Lindau syndrome (VHL). Multiple paraganglioma was associated with a germline mutation in SDHB. We found very good concordance between the results of CGH and aCGH techniques. Losses were observed more frequently than gains. All cases had a loss of chromosome 11 or 11p. Other aberrations were loss of chromosome 3 and 11 in sporadic pheochromocytoma, and loss of 3p and 11p in pheochromocytoma, which carried the VHL mutation. The deletion of chromosome 1p and other changes were observed in paragangliomas. We conclude that both array CGH and CGH analysis identified similar chromosomal regions involved in tumorigenesis of pheochromocytoma and paragangliomas, but we found 3 discrepancies between the methods. We didn't find any, of the proposed, molecular markers of malignancy in our benign cases and therefore we speculate that molecular cytogenetic examination may be helpful in separating benign and malignant forms in the future.
See more in PubMed
Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):160-5 PubMed
Horm Metab Res. 2009 Sep;41(9):687-96 PubMed
Am J Pathol. 2000 Feb;156(2):651-9 PubMed
Hum Pathol. 1985 Jun;16(6):580-9 PubMed
Mod Pathol. 2008 Apr;21(4):407-13 PubMed
Arch Surg. 1990 Aug;125(8):978-81 PubMed
Endocr Relat Cancer. 2009 Jun;16(2):505-13 PubMed
Pathol Int. 2008 Jul;58(7):415-20 PubMed
Hum Pathol. 2006 Jun;37(6):749-54 PubMed
J Med Genet. 1995 Dec;32(12):934-7 PubMed
Oncogene. 2004 May 20;23(23):4076-83 PubMed
Cancer Genet Cytogenet. 2010 Mar;197(2):189-92 PubMed
Med Clin North Am. 1995 Jan;79(1):131-53 PubMed
Urol Clin North Am. 2000 Aug;27(3):393-402 PubMed
Hum Mutat. 2000;15(5):418-29 PubMed
Cancer. 2008 Oct 15;113(8):2020-8 PubMed
Oncogene. 2002 Feb 7;21(7):1117-22 PubMed
J Clin Invest. 1991 May;87(5):1691-9 PubMed
Genes Chromosomes Cancer. 2006 Jun;45(6):602-7 PubMed
Mod Pathol. 2004 Sep;17(9):1119-28 PubMed
Am J Pathol. 1999 Dec;155(6):1787-94 PubMed
Hormones (Athens). 2009 Jan-Mar;8(1):29-38 PubMed
Neoplasma. 2005;52(5):415-9 PubMed
Am J Pathol. 2000 Aug;157(2):353-9 PubMed
Ann N Y Acad Sci. 2006 Aug;1073:166-76 PubMed
Endocr Relat Cancer. 2004 Sep;11(3):423-36 PubMed
N Engl J Med. 1993 Nov 18;329(21):1531-8 PubMed
Pediatr Nephrol. 2009 May;24(5):943-50 PubMed
J Pediatr Surg. 2001 Mar;36(3):447-52 PubMed
Am J Hum Genet. 2001 Jul;69(1):49-54 PubMed
Leuk Lymphoma. 2008 Mar;49(3):451-61 PubMed
Lancet. 2005 Aug 20-26;366(9486):665-75 PubMed
